Literature DB >> 31103169

Development and application of a LC-HRMS/MS method for analyzing antihypertensive drugs in oral fluid for monitoring drug adherence.

Lilian H J Richter1, Cathy M Jacobs1, Felix Mahfoud2, Ingrid Kindermann2, Michael Böhm2, Markus R Meyer3.   

Abstract

Nonadherence to antihypertensive drugs therapy is known to be a serious issue in hypertension treatment. Liquid chromatography (LC) coupled to mass spectrometry (MS) was shown to allow the assessment of such nonadherence in blood and urine sample. However, their sampling may represent a logistical challenge and are often not favored by the patients. We questioned whether oral fluid (OF) might be an easier accessible alternative matrix for adherence monitoring of cardiovascular drugs (CD). A qualitative method for adherence monitoring of 78 commonly prescribed cardiovascular drugs in OF using LC high-resolution MS (LC-HRMS/MS) was therefore developed, validated, and used to study the presence of antihypertensive medication in OF. Selectivity, ion suppression and enhancement due coeluting analytes, carry over, limits of detection (LOD), limits of identification (LOI), recovery (RE), matrix effects (ME), and process efficiency (PE) were investigated. For demonstrating applicability, over 50 OF samples were investigated and data were compared to findings in blood and urine. Selectivity in OF was given for all compounds via their MS2 spectra and no total suppression of signals could be observed. Determined LOI in OF for ten analytes was higher than the given therapeutic plasma concentration. Furthermore, RE, ME, and PE were in acceptable ranges for more than 65% of the compounds. In total, 208 prescriptions of CD to 57 patients were analyzed and demonstrated the suitability of for adherence monitoring in principle. OF was comparable to plasma regarding the drug categories and the frequencies of hits, except for acidic compounds but more hits could be found in urine samples. A analytical method using OF as analytical matrix was successfully developed. Application showed that it might be a suitable alternative for adherence monitoring of selected drugs in the future, particularly those having no acidic function.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adherence monitoring; Cardiovascular drugs; LC-HRMS/MS; Oral fluid

Mesh:

Substances:

Year:  2019        PMID: 31103169     DOI: 10.1016/j.aca.2019.04.026

Source DB:  PubMed          Journal:  Anal Chim Acta        ISSN: 0003-2670            Impact factor:   6.558


  4 in total

1.  Adherence to Antihypertensive Drugs Assessed by Hyphenated High-Resolution Mass Spectrometry Analysis of Oral Fluids.

Authors:  Lucas Lauder; Sebastian Ewen; Michael Kunz; Lilian H J Richter; Cathy M Jacobs; Ingrid Kindermann; Michael Böhm; Markus R Meyer; Felix Mahfoud
Journal:  J Am Heart Assoc       Date:  2020-07-07       Impact factor: 5.501

2.  Quality assessment of environmental water by a simple and fast non-ionic hydrophobic natural deep eutectic solvent-based extraction procedure combined with liquid chromatography tandem mass spectrometry for the determination of plastic migrants.

Authors:  Álvaro Santana-Mayor; Bárbara Socas-Rodríguez; Ruth Rodríguez-Ramos; Antonio V Herrera-Herrera; Miguel Ángel Rodríguez-Delgado
Journal:  Anal Bioanal Chem       Date:  2021-02-03       Impact factor: 4.142

3.  A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring.

Authors:  Valeria Avataneo; Elvira Fanelli; Amedeo De Nicolò; Franco Rabbia; Alice Palermiti; Marco Pappaccogli; Jessica Cusato; Francesco Giuseppe De Rosa; Antonio D'Avolio; Franco Veglio
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

4.  Clinical Value of Emerging Bioanalytical Methods for Drug Measurements: A Scoping Review of Their Applicability for Medication Adherence and Therapeutic Drug Monitoring.

Authors:  Tanja R Zijp; Zamrotul Izzah; Daan J Touw; Job F M van Boven; Christoffer Åberg; C Tji Gan; Stephan J L Bakker
Journal:  Drugs       Date:  2021-11-01       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.